Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

atenolol (TENORMIN)


A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include Drug and Dietary Supplement Profiles where your selected drug is a secondary subject of discussion.


Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion.

Nebivolol (BYSTOLIC): Limited Use for Hypertension
April 2018
When the beta blocker nebivolol was approved by the FDA in 2007, we advised readers not to use the drug until 2015, in accordance with our seven-year rule. Find out why we now have designated nebivolol as Limited Use and whether it is the right choice for treating hypertension.
Beta Blockers Save Lives in COPD Patients After Heart Attacks
May 2014
If you have chronic obstructive pulmonary disease (COPD) and suffer or have suffered a heart attack, you should be treated with a beta blocker. Such treatment could save your life. Find out why and learn which beta blockers are safest for COPD patients.
New Hypertension Drug Poses Breathing Risks
May 2013
The article discusses possible breathing risks of nebivolol (BYSTOLIC)and how other, older drugs — just as effective as this relatively new high blood pressure drug — are preferred because more is known about their risks.
Do Not Use Azilsartan (EDARBI) for High Blood Pressure
July 2012
Find out why we recommend that you do not use the recently approved high blood pressure drug azilsartan.
Drug-Induced Cognitive Impairment: Part One
March 2009
The article lists 57 different drugs that can cause dementia if used. This can be even more problematic if more than one of these drugs is being taken. These drugs are only one class of drugs that can cause mental deterioration and next month's issue will discuss additional drugs that can also impair thinking.
Nonsteroidal Anti-Inflammatory Drugs Can Make Blood Pressure Hard to Control
February 2009
Twenty different NSAIDS (nonsteroidal antiinflammatory drugs) are listed in this article that can adversely affect your blood pressure control. The article discusses the way in which this happens and what you can do about it.
A Review of Ranolazine (RANEXA) For Chronic Chest Pain
March 2007
Although the FDA medical officer in charge of reviewing ranolazine recommended that ranolazine's professional product labeling display a black box warning about potential disruption in the heart's electrical cycle, the drug does not have a black box warning.
Oxybutynin Patches (OXYTROL): A Grossly Overpriced Product For Overactive Bladder
July 2003
You should check the list of drugs that can cause loss of bladder control before starting drug treatment for this condition. You may be able to change from a drug that causes loss of bladder control to a drug that does not or alter the dose. This may be enough to solve the problem.
The Calcium Channel Blocker Verapamil (COVERA HS) For High Blood Pressure - Manufacturer Halts Important Clinical Trial
June 2003
This study does provide additional support to what the National Institutes of Health and the Health Research Group have been saying for years: low-dose hydrochlorothiazide should be the first drug used in the treatment of mild to moderate high blood pressure.
Written Drug Information Sheets Distributed by Pharmacists Fail to Meet Minimum Quality Standards
August 2002
The Food and Drug Administration (FDA) announced on June 18, 2002, the results of a national study to determine the extent of distribution and the quality of unregulated written drug information, known as “patient information leaflets” (PILs), produced by commercial information vendors to be disseminated by pharmacists to drug consumers when prescriptions are filled. The study’s results were appalling.


Search results below include Additional Information from Public Citizen where your selected drug is a secondary subject of discussion.

Comments before FDA Drug Safety Advisory Committee on Patient Drug Information (HRG Publication #1629)
The failure of the private sector to meet the quality goals established in The Action Plan and thus the failure to achieve the distribution goal of 75 percent of patients getting scientifically accurate information leaves only one option under Public Law 104-180: the Secretary [Department of Health and Human Services] shall seek public comment on other initiatives that may be carried out to meet such goals.